olopatadine intranasal (Rx)

Brand and Other Names:Patanase
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

nasal spray

  • 6% (665mcg/100 microliters spray)

Seasonal Allergic Rhinitis

2 sprays per nostril q12hr

Dosage Forms & Strengths

nasal spray

  • 6% (665mcg/100 microliters spray)

Seasonal Allergic Rhinitis

<6 years: Safety and efficacy not established

6-12 years: 1 spray per nostril q12hr

>12 years: 2 sprays per nostril q12hr

Next:

Adverse Effects

>10%

Bitter taste (12.8%; 1% pediatric)

Respiratory epistaxis (3-25%)

1-10%

Headache (4.4%)

Depression (2%)

Fatigue (1%)

Somnolence (1%)

Weight gain (1%)

Epistaxis (3.2%; 5.7% pediatric)

Upper respiratory tract infection (2.6% pediatric)

Pharyngolaryngeal pain (2.2%)

Postnasal drip (1.5%)

Cough (1.4%)

Urinary tract infection (1.2%)

Upper respiratory tract infection in children (3%)

<1%

CPK elevation

Dry mouth

Anosmia

Hyposmia

Nasopharyngitis

Throat irritation

Influenza

Previous
Next:

Warnings

Contraindications

Hypersensitivity

Cautions

May cause epistaxis, nasal ulceration, or nasal septal perforation

Avoid with nasal disease other than allergic rhinitis

May impair mental/physical abilities required for hazardous tasks (eg, driving, operating machinery)

Avoid concurrent use of alcohol or other CNS depressants (possible additive sedation)

Previous
Next:

Pregnancy & Lactation

Pregnancy

Published data from postmarketing experience with antihistamines, have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

However, there are no published human data specific to this drug

Animal data

  • In animal reproductive studies, oral administration of olopatadine hydrochloride to pregnant rats and rabbits caused a decrease in number of live fetuses at maternal doses approximately 110 and 1460 times the maximum recommended human daily intranasal dose (MRHDID) on a mg/m2 basis, respectively

Lactation

  • There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production; although orally administered drug is present in rat milk, there is no information about nasally administered drug
  • It is not known whether topical nasal administration could result in sufficient systemic absorption to produce detectable quantities in human breast milk
  • The developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breast fed infant from drug or from underlying maternal condition

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Antihistamine (H1 antagonist); inhibits release of histamine from mast cells.

Pharmacokinetics

Half-Life: 8-12 hr

Onset of action: 30 min (seasonal allergy)

Absorption: Systemic 57%

Bioavailability 57%

Peak Plasma Time: 0.25-2 hr

Peak Plasma Concentration: 23.3 ng/mL

Protein Bound: 55% (predominantly albumin)

Metabolites: N-desmethyl olopatadine; olopatadine N-oxide

Metabolism: Liver; not extensive

Excretion: Urine (60-70% unchanged); feces (17%)

Previous
Next:

Administration

Intranasal Administration

Prime nasal spray before initial use and when not in use for >7 days

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.